Ventrolateral preoptic nucleus

Structure

At least 80% of neurons in the VLPO that project to the ascending arousal system are GABAergic (neurons that produce GABA). In vitro studies in rats have shown that many neurons in the VLPO that are inhibited by norepinephrine or acetylcholine are multipolar triangular shaped cells with low threshold spikes. These triangular multipolar neurons exist in two sub-populations in the VLPO:

• Type 1 – inhibited by serotonin.
• Type 2 – excited by serotonin and adenosine.

As adenosine accumulates during wakefulness it is likely that type 2 cells play a role in sleep induction.

The remaining third of neurons in the VLPO are excited by norepinephrine. Their role is unclear.

In mice, all galaninergic neurons of the VLPO are inhibited by norepinephrine and excited by adenosine, although serotonin still differentiates Type 1 and Type 2 neurons.

Function

Sleep/wakefulness

In the early 20th century, Constantin von Economo noted that humans who had encephalitis with lesions in the anterior hypothalamus had insomnia, and proposed a sleep-promoting influence from that area. Animal studies in the mid-20th century in rats and cats confirmed that very large lesions in the preoptic area and basal forebrain resulted in insomnia but did not identify the cell group that was responsible. In 1996, Sherin and colleagues reported the presence of a cell group in the VLPO that expresses cFos (a protein often found in neurons that have recently been active) during sleep, and that these neurons contain the inhibitory neurotransmitters GABA and galanin. These same neurons receive inputs from the median preoptic nucleus (MnPO) and were found to innervate components of the ascending arousal system, including the tuberomammillary nucleus (TMN) and other components of the lateral hypothalamus; the raphe nuclei; the locus coeruleus (LC); the pedunculopontine (PPT) and laterodorsal tegmental nuclei (LDT); and the parabrachial nucleus (PB). More recent studies using opto- or chemogenetic activation of VLPO neurons have confirmed that they promote sleep.

The sleep-promoting effects of the VLPO neurons is thought to be due to release of GABA and possibly galanin that suppresses firing of arousal system neurons. As the VLPO is also inhibited by neurotransmitters released by components of the arousal systems, such as acetylcholine and norepinephrine, a current theory has proposed that the VLPO and the arousal system form a "flip-flop" circuit. This term from electrical engineering denotes a circuit in which mutual inhibition means that each component of the circuit, as it turns on, turns the other off, resulting in rapid transitions from one state (wake or sleep) to the other, with minimal time in transition states. This theory has been used to create mathematical models that explain much of the wake-sleep behavior in animals, including in pathological states and responses to drugs. Orexin neurons in the posterior lateral hypothalamus potentiate neurons in the ascending arousal system and help stabilize the brain in the waking state (and consolidated wakefulness, which builds up homeostatic sleep drive, helps stabilize the brain during later sleep). The loss of orexin neurons in the disorder narcolepsy destabilizes the wake-sleep switch, resulting in overwhelming sleep episodes during the waking day, as well as more frequent awakenings from sleep at night.

Circadian rhythm

There is a strong circadian rhythm of sleep in mammals. The "master clock" for circadian rhythms in mammals is the suprachiasmatic nucleus (SCN). The SCN has little if any projection directly to the VLPO neurons. Instead, they project strongly to the adjacent subparaventricular zone, which in turn contains inhibitory GABAergic neurons that innervate the dorsomedial nucleus of the hypothalamus. Lesions of the dorsomedial nucleus almost completely eliminate the circadian rhythm of sleep. GABAergic neurons in the dorsomedial nucleus innervate the VLPO, and glutamatergic neurons innervate the lateral hypothalamus, suggesting that the dorsomedial nucleus mainly promotes wakefulness during the active period (daytime for humans).

Clinical significance

Insomnia

Elderly human patients with more galanin neurons in their intermediate nucleus (the human equivalent of the VLPO galanin neurons in rodents) have better, more continuous sleep. A reduced number of VLPO neurons is associated with more fragmented sleep (more awakenings throughout the night).

Lesions in the VLPO in rats results in 50-60% decrease in NREM sleep time and prolonged insomnia. More recent research suggests that stress-induced insomnia could be due to an imbalance of input to arousal system and VLPO neurons.

Sedative/hypnotic drugs

Many sedative/hypnotic drugs act by binding to and potentiating GABA-A receptors. These include older drugs such as ethanol, chloral hydrate and barbiturates, as well as newer benzodiazepines and "non-benzodiazepine" drugs (such as zolpidem, which bind to the same receptor but have a different chemical configuration), and even anesthetics such as propofol and isoflurane. As the VLPO inputs to the arousal system use this same receptor, these drugs at low doses essentially act by potentiating the VLPO, producing a sleepy state. Animal studies show that VLPO neurons show cFos activation after sedative doses of these drugs, and that VLPO lesions produce resistance to their sedative effects. However, at high doses that produce a surgical plane of anesthesia, these drugs have much more widespread inhibitory effects, that do not depend upon the VLPO. Studies have shown that multiple sedative/hypnotic drugs that act by potentiating GABA-A receptors, including ethanol, chloral hydrate, propofol and gas anesthetics such as isoflurane, at sedative doses increase the activity of the VLPO neurons in mice. This finding suggests that at relatively low sedative doses, these medications may have a common mechanism of action, which includes potentiating the firing of VLPO neurons. High doses used in surgical anesthesia, however, reduce activity of neurons throughout the nervous system.

References

References

1. (December 2010). "Sleep state switching". Neuron.
2. (October 2005). "Hypothalamic regulation of sleep and circadian rhythms". Nature.
3. (September 2014). "The GABAergic parafacial zone is a medullary slow wave sleep-promoting center". Nat. Neurosci..
4. (December 2015). "The Neurobiology of Sleep and Wakefulness". The Psychiatric Clinics of North America.
5. (June 2015). "Turning a Negative into a Positive: Ascending GABAergic Control of Cortical Activation and Arousal". Front. Neurol..
6. (September 2017). "Slow-wave sleep is controlled by a subset of nucleus accumbens core neurons in mice". Nature Communications.
7. (January 1996). "Activation of ventrolateral preoptic neurons during sleep". Science.
8. (July 2012). "Control of sleep and wakefulness". Physiological Reviews.
9. (April 2000). "Identification of sleep-promoting neurons in vitro". Nature.
10. (December 2019). "Structural and functional connections between the median and the ventrolateral preoptic nucleus". Brain Structure & Function.
11. (2001). "An adenosine A2a agonist increases sleep and induces Fos in ventrolateral preoptic neurons". Neuroscience.
12. (March 2023). "Prostaglandin D₂ Controls Local Blood Flow and Sleep-Promoting Neurons in the VLPO via Astrocyte-Derived Adenosine". ACS Chemical Neuroscience.
13. (October 2016). "Serotonin differentially modulates excitatory and inhibitory synaptic inputs to putative sleep-promoting neurons of the ventrolateral preoptic nucleus". Neuropharmacology.
14. (January 2016). "Astrocyte-derived adenosine is central to the hypnogenic effect of glucose". Scientific Reports.
15. (October 2016). "Serotonin differentially modulates excitatory and inhibitory synaptic inputs to putative sleep-promoting neurons of the ventrolateral preoptic nucleus". Neuropharmacology.
16. (November 2016). "Serotonin and sleep-promoting neurons". Oncotarget.
17. (December 2019). "Structural and functional connections between the median and the ventrolateral preoptic nucleus". Brain Structure & Function.
18. (October 2018). "Galanin neurons in the ventrolateral preoptic area promote sleep and heat loss in mice". Nature Communications.
19. (April 2007). "A quantitative model of sleep-wake dynamics based on the physiology of the brainstem ascending arousal system". Journal of Biological Rhythms.
20. (2014). "A physiologically based model of orexinergic stabilization of sleep and wake". PLOS ONE.
21. (November 2003). "Critical role of dorsomedial hypothalamic nucleus in a wide range of behavioral circadian rhythms". The Journal of Neuroscience.
22. (December 2015). "Projections from the subparaventricular zone define four channels of output from the circadian timing system". The Journal of Comparative Neurology.
23. (May 2000). "Effect of lesions of the ventrolateral preoptic nucleus on NREM and REM sleep". The Journal of Neuroscience.
24. (October 2008). "Neural circuitry of stress-induced insomnia in rats". The Journal of Neuroscience.
25. (June 2008). "Role of endogenous sleep-wake and analgesic systems in anesthesia". The Journal of Comparative Neurology.
26. (November 2012). "Direct activation of sleep-promoting VLPO neurons by volatile anesthetics contributes to anesthetic hypnosis". Current Biology.
27. (December 2011). "The ventrolateral preoptic nucleus is not required for isoflurane general anesthesia". Brain Research.